These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Long-term safety of tiagabine. Kälviäinen R Epilepsia; 2001; 42 Suppl 3():46-8. PubMed ID: 11520323 [TBL] [Abstract][Full Text] [Related]
9. International experience with tiagabine add-on therapy. Ben-Menachem E Epilepsia; 1995; 36 Suppl 6():S14-S21. PubMed ID: 8595788 [TBL] [Abstract][Full Text] [Related]
10. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Crawford P; Meinardi H; Brown S; Rentmeester TW; Pedersen B; Pedersen PC; Lassen LC Epilepsia; 2001 Apr; 42(4):531-8. PubMed ID: 11440349 [TBL] [Abstract][Full Text] [Related]
11. Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy. Kälviäinen R J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():63-7. PubMed ID: 10030435 [TBL] [Abstract][Full Text] [Related]
14. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Adkins JC; Noble S Drugs; 1998 Mar; 55(3):437-60. PubMed ID: 9530548 [TBL] [Abstract][Full Text] [Related]
15. GABI-balance--a non-interventional observational study on the effectiveness of tiagabine in add-on therapy in partial epilepsy. Chmielewska B; Stelmasiak Z Neurol Neurochir Pol; 2008; 42(4):303-11. PubMed ID: 18975234 [TBL] [Abstract][Full Text] [Related]
16. Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint. Loiseau P Epilepsia; 1999; 40 Suppl 9():S14-9. PubMed ID: 10612357 [TBL] [Abstract][Full Text] [Related]
17. [Characteristics and indications of tiagabine]. Casas-Fernández C; Domingo-Jiménez R Rev Neurol; 2002 Sep; 35 Suppl 1():S96-S100. PubMed ID: 12373661 [TBL] [Abstract][Full Text] [Related]